MedPage Today) — SAVANNAH, Ga. — Inebilizumab (Uplizna) had clinically meaningful efficacy and a favorable safety profile among people with generalized myasthenia gravis (gMG), topline data from the MINT trial showed.
The anti-CD19 monoclonal…
Read More